{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+intravenously&page=2",
    "query": {
      "intervention": "Saline intravenously",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+intravenously&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T00:44:59.878Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00722098",
      "title": "Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "DC Vaccine & Cyclophosphamide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DC Vaccine & Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2008-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-08",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722098"
    },
    {
      "nct_id": "NCT02540226",
      "title": "Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Intravenous tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Topical tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Intravenous saline",
          "type": "DRUG"
        },
        {
          "name": "Topical saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 76,
      "start_date": "2015-11-19",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-25",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02540226"
    },
    {
      "nct_id": "NCT05425719",
      "title": "Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "MB-102",
          "type": "DRUG"
        },
        {
          "name": "MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "MediBeacon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2022-06-14",
      "completion_date": "2023-02-15",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 5,
      "location_summary": "Edgewater, Florida • Chicago, Illinois • Saint Paul, Minnesota + 2 more",
      "locations": [
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05425719"
    },
    {
      "nct_id": "NCT02663622",
      "title": "Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Hematopoietic Stem Cell Transplantation",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Efprezimod alfa",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-09-19",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663622"
    },
    {
      "nct_id": "NCT01579513",
      "title": "Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Congenital Heart Disease",
        "Disorder of Fetus or Newborn"
      ],
      "interventions": [
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "Up to 30 Days"
      },
      "enrollment_count": 190,
      "start_date": "2012-06",
      "completion_date": "2018-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Charleston, South Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579513"
    },
    {
      "nct_id": "NCT01522196",
      "title": "A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Crisis"
      ],
      "interventions": [
        {
          "name": "Varespladib",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Normal Saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Anthera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2012-02",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522196"
    },
    {
      "nct_id": "NCT04944862",
      "title": "A Study of CDX-0159 in Patients With Prurigo Nodularis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prurigo Nodularis"
      ],
      "interventions": [
        {
          "name": "CDX-0159",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-11-08",
      "completion_date": "2023-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 7,
      "location_summary": "Tempe, Arizona • Miami, Florida • Troy, Michigan + 4 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04944862"
    },
    {
      "nct_id": "NCT01842035",
      "title": "Heart Rate Response to Regadenoson and Sudden Cardiac Death",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Left Ventricular Systolic Dysfunction",
        "Sudden Cardiac Death"
      ],
      "interventions": [
        {
          "name": "regadenoson",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 90,
      "start_date": "2013-02",
      "completion_date": "2022-07",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01842035"
    },
    {
      "nct_id": "NCT00005908",
      "title": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasm"
      ],
      "interventions": [
        {
          "name": "Docetaxel - Dose A",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel - Dose B",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine - Dose B",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine - Dose A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2000-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2013-03-19",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005908"
    },
    {
      "nct_id": "NCT00532155",
      "title": "A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma",
        "Non Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel (Taxotere®)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone (pre- and post-medication for docetaxel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 913,
      "start_date": "2007-09",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-30T00:44:59.878Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532155"
    }
  ]
}